.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Sarepta and Roche will share the monitors' findings with EMA to resolve a tempor...
Thirteenth meeting of the industry stakeholder platform on research and developm...
Highlight report - 13th Industry stakeholder platform on research and developmen...
Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putti...
SMS guidance for external users
Mehmet Oz, a physician and TV personality, takes office as HHS lays off thousand...
As the RSV vaccine field grapples with a significantly reduced market size thank...
Human medicines European public assessment report (EPAR): Roclanda, latanoprost ...
After a drawn-out acquisition that closed in 2023, U.K. biotech F-star Therapeut...
Human medicines European public assessment report (EPAR): Ajovy, fremanezumab, D...
Human medicines European public assessment report (EPAR): Opsumit, macitentan, D...
Human medicines European public assessment report (EPAR): SomaKit TOC, edotreoti...
Healthcare providers face increasing complexity in prescribing due to rising cos...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
Must read biotech news stories, brought to you by The Readout.
Human medicines European public assessment report (EPAR): Stoboclo, denosumab, D...
Take a look at the biggest updates to the fast-moving pharma landscape.
This week on "The Top Line," we dive into our special report ranking the top pha...
Servier’s decision to exit a Parkinson’s disease pact has triggered belt tighten...
In response to a request from the European Medicines Agency following the death ...
Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, r...
Human medicines European public assessment report (EPAR): Avtozma, tocilizumab, ...
Human medicines European public assessment report (EPAR): Rivastigmine Hexal, ri...